eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2015-01-08 1 2 371 374 458 article Nwobodo 1 P. O. Okonkwo 2 Department of Pharmacology and Therapeutics, College of Medicine, Enugu State University of Science and Technology Enugu (Nigeria). Department of Pharmacology and Therapeutics, College of Medicine, University of Nigeria (Nigeria). Nigeria has changed the recommended treatment for acute uncomplicated P.falciparum malaria to artemisinin-based combination therapy (ACT). However, non-ACT regimen of Amodiaquine and Sulfadoxine-pyrimethamine (AQ + SP) are reported to be effective, safe, readily available and affordable compared to ACT. In a randomized controlled trial involving 120 children aged 6 to 59 months (M:F, 1:1.32) with clinically characterized malaria; the efficacy of non-ACT combination, (AQ + SP) and ACT combination, Artesunate plus Amodiaquine (AT + AQ) was evaluated. Results revealed that mean Fever Clearance Time (FCT) of 28.3+2.3 hours in non-ACT was not significantly different (P>0.05) from 25.4+2.3 hours reported for ACT combination. Similarly, there was no statistically significant difference (P>0.05) in the mean Parasite Clearance Time (PCT) for both ACT and non-ACT combinations. Again, there was no statistically significant difference (P>0.05) in the haematocrit and axillary temperatures between pre and post-treatment in both non-ACT and ACT treatment groups. In conclusion, the AQ + SP combination (non-ACT) is strongly recommended as a cost effective and therapeutic alternative to ACT for the treatment of uncomplicated P.falciparum malaria especially in under five children in Enugu State, Nigeria. https://biomedpharmajournal.org/vol1no2/comparative-study-on-the-efficacy-of-artesunate-plus-amodiaquine-combination-act-and-amodiaquine-plus-sulfadoxine-pyrimethamine-combination-non-act-in-the-treatment-of-acute-uncomplicated-malaria/ ACT efficacy malaria non-ACT